Skip to main content

Lung Cancer

Clinical Lead: Dr Craig Dyer, Cardiff and Vale University Health Board
Deputy Lead: Dr Emma Watkins, Cwm Taf Morgannwg University Health Board


This page provides information and guidance on lung cancer for health care professionals. 

Information for patients can be found on our patient hub.

If would like further information on the Lung CSG please click here to contact us.

The National Optimal Pathway for lung cancer was developed in conjunction with the lung CSG to support the implementation of the the Single Cancer Pathway (SCP) in Wales.

The Welsh Thoracic Oncology Group (WTOG) has revised the Lung Cancer National Optimal Pathway (NOPLC).  This second edition (2022) of the NOLCP reflects the changing developments in the treatment of lung cancer since the NOLCP was first described. A standardised approach to molecular and genetic testing of biopsies allows patients with both early and advanced stage lung cancer to benefit from an increasing range of novel therapies and improve access to clinical trials.

NOP Lung Cancer and Genomics

Contact details can be accessed via the NHS Wales Global address list. If you do not have access to this please click here to contact us.


Health Board/MDT MDT Lead MDT Frequency
Aneurin Bevan UHB Dr Mat Jones

Thursdays 11:30 am


Betsi Cadwaladr UHB –  Ysbyty Glan Clwyd Dr Sakkarai Ambalavanan

Wednesdays 11am


Betsi Cadwaladr UHB –  Ysbyty Gwynedd Dr Ali Thahseen

Tuesdays 1pm


Betsi Cadwaladr UHB – Ysbyty Wrexham Maelor Chair is shared by the team

Wednesdays 8am


Cardiff & Vale UHB Dr Diane Parry

Thursdays 12:15pm


Cwm Taf UHB – Prince Charles Dr Alex Jones

Wednesdays 8:30am


Cwm Taf UHB – Princess of Wales Dr Emma Watkins

Thursdays 8:30pm


Cwm Taf UHB – Royal Glamorgan Dr Sinan Eccles

Tuesdays 8:30am


Hywel Dda UHB Dr Gareth Collier

Thursdays 1pm


Swansea Bay UHB Dr Emrys Evans

Mondays 9:30am 


The Welsh Thoracic Oncology Group Meeting 2022 took place on 1st October 2021. To access the recording please click here to contact us.